Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction

TechNet21 is generously supported by the Bill and Melinda Gates Foundation, under the oversight of WHO and UNICEF. The information in this forum is provided by users, as a service. All contributions are reviewed prior to posting, and all postings are attributed to the authors. The details given in emails will not be voluntarily shared or sold to any outside company and will only be used for verification and to identify postings, if necessary. The authors are solely responsible for their submissions, and the readers are solely responsible for the interpretation of these submissions. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to this forum. For posts where the author is a WHO staff member, the author alone is responsible for the views expressed and they do not necessarily represent the decisions, guidelines, recommendations or policies of WHO.